Electronic Resource
Updated results of the aspen trial from a cohort of patients with wild-type myd88 waldenstrom macroglobulinemia (myd88wt wm).
| العنوان: | Updated results of the aspen trial from a cohort of patients with wild-type myd88 waldenstrom macroglobulinemia (myd88wt wm). |
|---|---|
| المؤلفون: | Buske C., Dimopoulos M., Garcia Sanz R., Lee H.-P., Trneny M., Varettoni M., Opat S., D'Sa S., Owen R.G., Cull G., Mulligan S., Czyz J., Castillo J., Motta M., Siddiqi T., Gironella Mesa M., Granell Gorrochategui M., Talaulikar D., Zinzani P.L., Askari E., Grosicki S., Oriol A., Kloczko J., Tedeschi A., Leblond V., Chan W.Y., Schneider J., Cohen A., Huang J., Tam C.S. |
| بيانات النشر: | S. Karger AG Netherlands 2022-01-12 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Introduction: Inhibitors of Bruton's tyrosine kinase (BTK) have shown significant activity in patients with MYD88 mutation-positive (MYD-88mut+) WM. However, lower response rates and shorter progression-free survival have been reported in patients with WM who lack such mutations (N Engl J Med. 2015;372:1430). The ASPEN trial (NCT03053440) evaluated zanubrutinib, a potent and selective BTK inhibitor, in patients with MYD88WT WM. Here, we present the safety and efficacy of zanubrutinib in these patients. Method(s): At study entry, bone marrow MYD88 mutations were assessed by a central laboratory (NeoGenomics). Based on these results, patients were assigned to cohort 1 (MYD88mut+) or cohort 2 (MYD88WT or unknown mutation status). Patients received zanubrutinib 160 mg twice daily until disease progression. Result(s): In total, 28 patients were enrolled in cohort 2, of which 26 were centrally confirmed as MYD88WT. Median age of patients was 72 years; five patients were treatment-naive and 23 patients had relapsed/refractory (>=1 prior therapy) WM. Most patients had intermediate-risk (39.3%) or high-risk (42.9%) disease, as defined by the International Prognostic Scoring System for WM. At median follow-up of 17.9 months, two patients discontinued zanubrutinib due to adverse events (AEs), and six experienced disease progression; there were no cases of disease transformation. In patients with confirmed MYD88WT, the overall response rate by independent review was 80.8%, with a major response rate of 50.0%, including a very good partial response rate of 26.9%. The progression-free survival event-free rate at 12 months was 72.4%. The most frequently reported AEs were diarrhea, anemia, contusion, pyrexia, and upper respiratory tract infection. Major hemorrhage was reported in two patients, and atrial fibrillation was reported in one patient. There were no fatal AEs. Conclusion(s): Zanubrutinib showed clinically meaningful antitumor activity, including achieving major responses |
| مصطلحات الفهرس: | Conference Abstract |
| URL: | Oncology Research and Treatment LibKey Link |
| الاتاحة: | Open access content. Open access content |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/47183 Oncology Research and Treatment. Conference: Jahrestagung der Deutschen, Osterreichischen und Schweizerischen Gesellschaften fur Hamatologie und Medizinische Onkologie. Berlin Germany. 44(SUPPL 2) (pp 153), 2021. Date of Publication: 2021. https://repository.monashhealth.org/monashhealthjspui/handle/1/47183 (Buske) CCC Ulm-Universitatsklinikum Ulm, Ulm, Germany (Dimopoulos) National and Kapodistrian University of Athens, Athens, Greece (Garcia Sanz) Hospital Universitario de Salamanca, Salamanca, Spain (Lee) Flinders Medical Centre, Adelaide, Australia (Trneny) Vseobecna fakultni nemocnice v Praze, Prague, Czechia (Varettoni) Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (Opat) Monash Health, Clayton, Australia (Opat) Monash University, Clayton, Australia (D'Sa) University College London Hospital Foundation Trust, London, United Kingdom (Owen) St James University Hospital, Leeds, United Kingdom (Cull) Sir Charles Gairdner Hospital, Perth, Australia (Cull) University of Western Australia, Perth, Australia (Mulligan) Royal North Shore Hospital, Sydney, Australia (Czyz) Szpital Uniwersytecki nr 2 im Dr. Jana Biziela, Bydgoszcz, Poland (Czyz) Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Department of Hematology, Bydgoszcz, Poland (Castillo) Dana-Farber Cancer Institute, Boston, United States (Castillo) Harvard Medical School, Boston, United States (Motta) AO Spedali Civili di Brescia, Lombardia, Italy (Siddiqi) City of Hope National Medical Center, Duarte, United States (Gironella Mesa) Hospital Universitario Vall d'Hebron, Barcelona, Spain (Granell Gorrochategui) Hospital de La Santa Creu i Sant Pau, Barcelona, Spain (Talaulikar) Australian National University, Canberra, Australia (Zinzani) Institute of Hematology 'Seragnoli' University of Bologna, Bologna, Italy (Askari) Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain (Grosicki) Medical University of Silesia, Department of Hematology and Cancer Prevention, Health Sciences Faculty, Katowice, Poland (Oriol) Institut Catala d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain (Kloczko) Uniwersytecki Szpital Kliniczny w Bialymstoku, Podlaskie, Poland (Tedeschi) ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy (Leblond) Sorbonne University, Pitie Salpetriere Hospital, Paris, France (Chan, Schneider, Cohen, Huang) BeiGene USA, Inc., San Mateo, United States (Tam) Peter MacCallum Cancer Centre, Melbourne, Australia (Tam) St Vincent's Hospital, Fitzroy, Australia (Tam) University of Melbourne, Parkville, Australia (Tam) Royal Melbourne Hospital, Parkville, Australia (Opat) Monash Health, Clayton, Australia 1310346666 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1310346666 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |